Researchers reported in Science Translational Medicine two small-molecule-controlled genome editing systems—PRINCE and Little Prince—that keep CRISPR activity largely silent without drug and switch it on when induced. Led by Dr. Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, the dual systems are designed to improve the controllability of gene editing in living tissues, addressing a key limitation of conventional CRISPR deployments. The work focuses on using dual small-molecule control to modulate editing activity and reduce unintended activity during off-target windows, aiming for tighter temporal precision in in vivo applications. This publication adds to the growing library of drug-inducible CRISPR toolkits, which are increasingly being positioned as enabling layers for next-generation therapeutic gene editing programs.